Skip to main content
. 2019 Jan 21;8(1):13. doi: 10.3390/antib8010013

Figure 2.

Figure 2

Nanobody-based strategies targeting the immune stroma of tumors. Nanobody-derived immunomodulatory molecules are under investigation to increase anti-tumor immunity (orange arrows) and prevent tumor-driven immune suppression (blue arrows). TAA: Tumor associated antigen; IC: Immune checkpoint; ARD: Antibody recruiting domain.